Last updated: September 4, 2026
The sodium sulfate, potassium sulfate, and magnesium sulfate oral solution market is led by SUPREP Bowel Prep Kit, an FDA-approved prescription bowel preparation for adults undergoing colonoscopy. The active salts are established and relatively difficult to differentiate. Commercial value is concentrated in taste masking, low-volume administration, packaging, manufacturing reliability, patient adherence, and generic supply economics.
The reference product is associated with NDA 022372 and contains two 6-ounce bottles. Each bottle contains sodium sulfate 17.5 g, potassium sulfate 3.13 g, and magnesium sulfate 1.6 g. The labeled inactive ingredients include citric acid, flavoring, malic acid, potassium benzoate, purified water, and sucralose.[1]
What is sodium sulfate, potassium sulfate, and magnesium sulfate oral solution?
Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution is an osmotic bowel-cleansing preparation. The sulfate salts retain water in the intestinal lumen, producing watery stool and cleansing the colon before diagnostic or surgical procedures.[1]
| Product attribute |
Reference-product profile |
| Dosage form |
Oral solution concentrate |
| Administration |
Diluted before use |
| Active ingredients per 6-ounce bottle |
Sodium sulfate 17.5 g; potassium sulfate 3.13 g; magnesium sulfate 1.6 g |
| Kit configuration |
Two bottles |
| Primary indication |
Colon cleansing before colonoscopy in adults |
| FDA reference product |
SUPREP Bowel Prep Kit |
| NDA |
022372 |
| Key excipients |
Citric acid, malic acid, flavoring, potassium benzoate, purified water, sucralose |
| Prescription status |
Prescription drug |
| Primary formulation challenge |
High salt load and strong mineral taste |
The product is not an ordinary ready-to-drink electrolyte beverage. It is a concentrated pharmaceutical solution that must be diluted with water according to the prescribing information. Administration also requires additional water or clear liquids to reduce dehydration and electrolyte risks.[1]
What excipients are used in the oral solution?
The excipient system has four functional roles: acidity control, preservation, flavor management, and palatability improvement.
| Excipient category |
Representative ingredient |
Commercial function |
| Acidulant |
Citric acid |
Controls pH and contributes sourness |
| Acidulant and flavor modifier |
Malic acid |
Extends sour profile and helps mask mineral notes |
| Sweetener |
Sucralose |
Reduces perceived bitterness without adding significant volume |
| Preservative |
Potassium benzoate |
Controls microbial growth in the aqueous concentrate |
| Flavor system |
Proprietary flavoring |
Masks sulfate, potassium, and magnesium taste |
| Vehicle |
Purified water |
Solubilizes active salts and excipients |
The formulation uses potassium benzoate rather than a sodium-based preservative. That choice limits additional sodium exposure, although the product already contains a substantial sodium sulfate load. Any reformulation must preserve preservative effectiveness under the product’s pH, ionic strength, storage conditions, and in-use dilution profile.
Why the acidulant system matters
Citric acid and malic acid do more than create sourness. They influence:
- pH and preservative performance;
- flavor release;
- perception of metallic and bitter notes;
- compatibility with flavor compounds;
- chemical stability during storage.
A single-acid formulation may reduce manufacturing complexity but can produce a sharper, less balanced taste. A mixed-acid system gives formulators more control over initial sourness and aftertaste.
Why sweetener selection is constrained
Sucralose provides high-intensity sweetness at low concentration. Alternative sweeteners, including acesulfame potassium, saccharin, steviol glycosides, and combinations of sweeteners, could create differentiation. Their use is constrained by aftertaste, regulatory precedent, stability, and interaction with acidic flavor systems.
Sugar-based formulations would increase caloric content and may reduce suitability for patients with diabetes or dietary restrictions. Polyols could introduce gastrointestinal effects that are undesirable in a bowel-preparation product.
What excipient strategy best supports a differentiated product?
The strongest strategy is to preserve the active salt composition while improving sensory performance and administration logistics.
Flavor masking
The principal opportunity is a flavor system designed specifically for high-ionic-strength solutions. Conventional fruit flavors can perform poorly because sulfate and magnesium notes persist after swallowing. Candidate systems include:
- citrus blends with controlled citric and malic acid ratios;
- berry and tropical profiles with high top-note intensity;
- cooling or vanillic modifiers used at low levels;
- bitterness blockers compatible with acidic aqueous products;
- encapsulated or emulsion-based flavors that improve persistence.
Flavor selection must be tested after dilution, not only in the concentrate. The diluted product is the form patients consume, and dilution changes acidity, aroma intensity, sweetness, and mineral perception.
Taste-masking technology
A product developer could use bitterness blockers, ion-pairing approaches, microencapsulated flavors, or multipart flavor systems. The technology must not reduce salt dissolution or produce visible haze after dilution.
The commercial advantage of a taste-masking platform is potentially broader than this product. The same technology may apply to:
- oral electrolyte solutions;
- magnesium-containing laxatives;
- pediatric mineral formulations;
- oral rehydration products;
- concentrated bowel-prep products;
- high-load liquid antibiotics.
Preservative optimization
Potassium benzoate is an established preservative option, but alternative systems may improve regulatory or supply-chain flexibility. Candidate approaches include sorbate-based systems, benzoate-sorbate combinations, or preservative-free packaging where microbiological controls justify the approach.
A preservative change is not a simple substitution. It can affect pH, flavor, container compatibility, extractables and leachables, and stability after opening. A new product would require preservative effectiveness testing and stability data under the applicable FDA requirements.[2]
Packaging and dosing convenience
The current two-bottle configuration creates opportunities in packaging rather than active chemistry. Potential improvements include:
- single-use bottles with clearer fill lines;
- integrated dilution containers;
- tamper-evident unit-dose packaging;
- child-resistant secondary packaging;
- peel-open administration guides;
- QR-linked multilingual instructions;
- carton designs that separate first-dose and second-dose instructions.
Packaging that reduces dosing errors can improve adherence and reduce pharmacy counseling time. Any design that changes the labeled volume, closure, or in-use storage conditions may require additional regulatory assessment.
What commercial opportunities exist in this market?
Commercial opportunities fall into five categories.
Generic and authorized-generic supply
The active ingredients are inexpensive, widely available inorganic salts. The value of a generic product depends on:
- consistent assay and impurity control;
- reliable dissolution;
- flavor performance;
- low-cost filling of high-density solutions;
- packaging economics;
- pharmacy channel access.
A generic that matches the reference product’s active composition but has inferior taste may face weak patient acceptance even if it receives FDA approval. The formulation and packaging should therefore be treated as commercial assets, not secondary manufacturing details.
Private-label and contract manufacturing
Contract manufacturers with experience in oral liquids, high-solids solutions, and preservative systems may supply regional or private-label products. The principal barriers are validated mixing, control of precipitation, filling accuracy, bottle compatibility, and quality testing for high ionic-strength solutions.
Premium patient-adherence products
A differentiated product could support premium pricing if it offers a measurable administration advantage. Possible claims include improved taste, smaller preparation burden, clearer instructions, or lower packaging complexity. Claims must be supported by formulation data and, where necessary, human sensory or adherence studies.
Institutional and payer contracts
Hospitals, ambulatory surgery centers, and health systems generally prioritize acquisition cost, supply reliability, formulary status, and patient outcomes. A product with a modest acquisition premium could compete if it reduces cancellations, incomplete preparation, nursing interventions, or repeat procedures.
Geographic expansion
The United States is the principal regulatory reference market for SUPREP. Other markets may use different bowel-preparation standards, labeling conventions, pack sizes, and electrolyte warnings. Expansion requires assessment of:
- local maximum daily electrolyte exposure;
- language-specific instructions;
- approved colonoscopy-preparation indications;
- preservative and sweetener acceptability;
- local medical-device or combination-product requirements;
- import and serialization rules.
How does this product compare with competing bowel preparations?
| Product type |
Main advantage |
Main commercial weakness |
| Sulfate oral solution |
Lower administered volume than some polyethylene glycol regimens |
Strong taste and electrolyte burden |
| Polyethylene glycol electrolyte solution |
Long regulatory history and broad clinical familiarity |
Larger fluid volume and lower patient convenience |
| Tablet-based bowel prep |
Avoids drinking a large volume of solution |
Requires swallowing many tablets and substantial accompanying liquid |
| Ready-to-drink lower-volume solutions |
Administration convenience |
Higher formulation and packaging cost |
| Sodium picosulfate-based preparations |
Established split-dose approach |
Different electrolyte and renal-risk considerations |
The central competitive variable is total patient burden. A lower-volume formulation has value only if patients can tolerate the taste and follow the required supplemental-fluid instructions.
What is the FDA regulatory status and Orange Book position?
The reference product is FDA-approved under NDA 022372 for adult colon cleansing before colonoscopy.[1] The product’s regulatory protection is materially different from a new chemical entity because the active salts are established ingredients and the product has a narrow procedural indication.
The relevant regulatory pathway for competing products is generally an abbreviated new drug application referencing the listed drug, subject to FDA requirements for pharmaceutical equivalence, bioequivalence where applicable, manufacturing quality, and labeling.[3]
Exclusivity timeline
The reference product was approved in 2010. Any original NDA exclusivity associated with that approval would not be a current commercial barrier. Competition is therefore more likely to depend on FDA approval status, listed patents, supply capability, contracts, and brand recognition.
Orange Book listings
The Orange Book should be evaluated for the current NDA 022372 listing, including any active patent entries, expiration dates, and associated use codes.[4] Product developers should not assume that an old formulation patent, a manufacturing patent, or a historical patent listing continues to block generic entry. The legal effect depends on current listing status, claim scope, expiration, pediatric extensions, and any litigation or settlement.
Paragraph IV challenges and litigation
A Paragraph IV certification may challenge a listed patent as invalid, unenforceable, or not infringed. For this product class, the practical assessment should focus on:
- whether any formulation patent remains listed;
- whether claims cover the specific active ratio or excipient combination;
- whether the claims cover the concentrate, diluted solution, or administration method;
- whether a generic applicant has filed a Paragraph IV certification;
- whether a 30-month stay or settlement affects launch timing.
No generic launch date should be inferred from patent expiration alone. FDA approval, litigation, settlement terms, manufacturing readiness, and commercial strategy can produce different launch outcomes.
How strong is the patent estate for sodium sulfate, potassium sulfate, and magnesium sulfate oral solution?
The core active-salt combination has limited intrinsic patent strength because the ingredients are known inorganic salts used in established medical and nonmedical applications. The strongest potential protection would more likely arise from:
- defined excipient ratios;
- taste-masking systems;
- specific pH ranges;
- preservative combinations;
- improved stability profiles;
- packaging and dosing configurations;
- manufacturing processes that prevent precipitation or content uniformity failures;
- method-of-use claims tied to a particular dosing sequence.
Composition claims must survive prior-art review and enablement scrutiny. A broad claim covering the salts in an aqueous bowel-preparation solution may face greater vulnerability than a narrowly defined claim directed to a validated flavor, stability, or packaging system.
Method-of-use protection is also limited by the established clinical purpose of bowel cleansing before colonoscopy. Any remaining value would likely come from a specific dosing regimen, patient population, or reduced adverse-event profile rather than the general indication.
What generic entry risks exist?
The highest generic-entry risk is substitution on price after active patents and regulatory exclusivity cease to constrain approval. The main countervailing risks are formulation quality and market access.
| Risk area |
Impact on launch |
| Taste inferior to the reference product |
Lower patient acceptance and weaker repeat prescribing |
| Supply disruption |
Creates opportunity for alternate suppliers |
| Preservative or stability failure |
Delays approval or causes recalls |
| Bottle or closure incompatibility |
Adds packaging remediation costs |
| Labeling differences |
Increases pharmacy and provider friction |
| Limited payer access |
Restricts volume despite FDA approval |
| Orange Book litigation |
Can delay commercial launch |
| High manufacturing cost |
Reduces ability to compete in tenders |
What are the licensing and partnership opportunities?
Licensing value is most credible in three areas:
- A validated taste-masking technology that can be applied to concentrated electrolyte solutions.
- A contract manufacturing platform capable of high-solids oral liquids and small-volume filling.
- A packaging system that improves split-dose compliance and reduces administration errors.
A licensee would likely require freedom-to-operate analysis covering excipient combinations, flavor compositions, container systems, manufacturing methods, and use claims. A formulation license without manufacturing scale-up data would have limited commercial value.
Key Takeaways
- The product is an established two-bottle sulfate bowel preparation associated with SUPREP and NDA 022372.
- The principal formulation opportunity is taste masking, not modification of the active salts.
- Citric acid, malic acid, sucralose, potassium benzoate, flavoring, and purified water form the key excipient platform.
- Commercial differentiation can come from flavor performance, packaging, dosing instructions, and manufacturing reliability.
- Generic competition is likely to focus on price and supply, while premium products must demonstrate better patient acceptance or lower administration burden.
- Original FDA exclusivity is not a current barrier based on the 2010 approval date.
- Current Orange Book patent listings, Paragraph IV certifications, litigation, and settlements must be assessed before assigning a generic launch date.
- The most defensible new intellectual property is likely to involve taste masking, stability, packaging, or manufacturing rather than the known sulfate combination.
FAQs
Can the sodium sulfate, potassium sulfate, and magnesium sulfate solution be reformulated without changing the active ingredients?
Yes. A developer can alter flavoring, acidulants, sweeteners, preservatives, packaging, and manufacturing parameters while maintaining the active salt composition. The changes may still require a regulatory supplement or new application pathway depending on their scope.
Which excipient is most important for improving patient acceptance?
The flavor system is usually the most commercially important variable, but flavor performance depends on the acidulant ratio, sweetener, dilution volume, and mineral taste. Testing only the concentrate can produce misleading results.
Is potassium benzoate necessary in every generic formulation?
No. A generic formulation may use another validated preservative system or a preservative-free design if microbiological control and stability requirements are satisfied. The alternative must be compatible with the product’s pH, ionic strength, packaging, and in-use conditions.
Could a ready-to-drink version replace the concentrated oral solution?
It could be developed, but the increased fill volume, shipping weight, packaging cost, and stability burden would reduce some of the commercial advantages of a concentrate. The product would need a clear administration or adherence benefit.
Are biosimilars relevant to this product?
No. This is a small-molecule salt solution, not a biologic. Competitive products would generally follow generic-drug pathways rather than the biosimilar pathway.
References
- U.S. Food and Drug Administration. (2010). SUPREP Bowel Prep Kit: Prescribing information, NDA 022372.
- U.S. Food and Drug Administration. (2014). Container closure systems for packaging human drugs and biologics: Guidance for industry.
- U.S. Food and Drug Administration. (2023). ANDA submissions: Content and format guidance for industry.
- U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
